Literature DB >> 33798500

Gout.

Nicola Dalbeth1, Anna L Gosling2, Angelo Gaffo3, Abhishek Abhishek4.   

Abstract

Gout is a common and treatable disease caused by the deposition of monosodium urate crystals in articular and non-articular structures. Increased concentration of serum urate (hyperuricaemia) is the most important risk factor for the development of gout. Serum urate is regulated by urate transporters in the kidney and gut, particularly GLUT9 (SLC2A9), URAT1 (SLC22A12), and ABCG2. Activation of the NLRP3 inflammasome by monosodium urate crystals with release of IL-1β plays a major role in the initiation of the gout flare; aggregated neutrophil extracellular traps are important in the resolution phase. Although presenting as an intermittent flaring condition, gout is a chronic disease. Long-term urate lowering therapy (eg, allopurinol) leads to the dissolution of monosodium urate crystals, ultimately resulting in the prevention of gout flares and tophi and in improved quality of life. Strategies such as nurse-led care are effective in delivering high-quality gout care and lead to major improvements in patient outcomes.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 33798500     DOI: 10.1016/S0140-6736(21)00569-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Translation, internal consistency, reliability and validity of the Thai version of Gout Assessment Questionnaire version 2.0 (GAQ 2.0).

Authors:  Nathrudee Phrintrakul; Antika Wongthanee; Nuntana Kasitanon; Worawit Louthrenoo
Journal:  Clin Rheumatol       Date:  2022-03-30       Impact factor: 2.980

Review 2.  Annual reports on hypertension research 2020.

Authors:  Masaki Mogi; Yukihito Higashi; Kanako Bokuda; Atsuhiro Ichihara; Daisuke Nagata; Atsushi Tanaka; Koichi Node; Yoichi Nozato; Koichi Yamamoto; Ken Sugimoto; Hirotaka Shibata; Satoshi Hoshide; Hitoshi Nishizawa; Kazuomi Kario
Journal:  Hypertens Res       Date:  2021-10-15       Impact factor: 3.872

3.  Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout.

Authors:  Edoardo Cipolletta; Laila J Tata; Georgina Nakafero; Anthony J Avery; Mamas A Mamas; Abhishek Abhishek
Journal:  JAMA       Date:  2022-08-02       Impact factor: 157.335

4.  Angiotensin type 2 receptor antagonism as a new target to manage gout.

Authors:  Luiz Ricardo Goulart; Thiago Neves Vieira; André L Lopes Saraiva; Rafaela Mano Guimarães; João Paulo Mesquita Luiz; Larissa Garcia Pinto; Veridiana de Melo Rodrigues Ávila; Jair Pereira Cunha-Junior; Peter Anthony McNaughton; Thiago Mattar Cunha; Juliano Ferreira; Cassia Regina Silva
Journal:  Inflammopharmacology       Date:  2022-09-29       Impact factor: 5.093

5.  The Mediation Effect of Body Composition on the Association Between Menopause and Hyperuricemia: Evidence From China National Health Survey.

Authors:  Huijing He; Li Pan; Feng Liu; Xiaolan Ren; Ze Cui; Lize Pa; Jingbo Zhao; Dingming Wang; Jianwei Du; Hailing Wang; Xianghua Wang; Xia Peng; Chengdong Yu; Ye Wang; Guangliang Shan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

Review 6.  The Interaction Between Dietary Fructose and Gut Microbiota in Hyperuricemia and Gout.

Authors:  Xin-Yu Fang; Liang-Wei Qi; Hai-Feng Chen; Peng Gao; Qin Zhang; Rui-Xue Leng; Yin-Guang Fan; Bao-Zhu Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Front Nutr       Date:  2022-06-22

Review 7.  Activation and Function of NLRP3 Inflammasome in Bone and Joint-Related Diseases.

Authors:  Tomohiko Murakami; Yuri Nakaminami; Yoshifumi Takahata; Kenji Hata; Riko Nishimura
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

Review 8.  Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.

Authors:  Hitoshi Nishizawa; Norikazu Maeda; Iichiro Shimomura
Journal:  Hypertens Res       Date:  2022-01-19       Impact factor: 3.872

Review 9.  Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development.

Authors:  Eder Orlando Méndez-Salazar; Gabriela Angélica Martínez-Nava
Journal:  Rheumatol Int       Date:  2021-09-29       Impact factor: 2.631

Review 10.  The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.

Authors:  Robert Eckenstaler; Ralf A Benndorf
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.